首页> 美国卫生研究院文献>other >sb203580 preconditioning recharges matrix-expanded human adult stem cells for chondrogenesis in an inflammatory environment – a feasible approach for autologous stem cell based osteoarthritic cartilage repair
【2h】

sb203580 preconditioning recharges matrix-expanded human adult stem cells for chondrogenesis in an inflammatory environment – a feasible approach for autologous stem cell based osteoarthritic cartilage repair

机译:sb203580预处理可在炎性环境中为基质扩增的人成体干细胞充电从而促进软骨形成–基于自体干细胞的骨关节炎修复的可行方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autologous stem cells are a promising cell source for cartilage regeneration; however, cell replicative senescence and joint posttraumatic inflammation provide challenges to bring this treatment modality to fruition. In this study, we hypothesized that preconditioning with p38 MAPK inhibitor (sb203580) would recharge decellularized extracellular matrix (dECM) expanded human synovium-derived stem cell (hSDSC) chondrogenesis in an inflammatory environment. We found that preconditioning with sb203580 greatly enhanced dECM expanded hSDSC proliferation and chondrogenic potential while supplementation with sb203580 in an induction medium dramatically retarded hSDSC chondrogenic differentiation, even for dECM expanded cells. We also found that sb203580 preconditioning enhanced matrix-expanded hSDSC chondrogenic capacity even in an interleukin-1 (IL-1) induced inflammatory environment. Non-detectable expression of HLA-DR in the hSDSCs grown on allogeneic dECM indicates the feasibility of commercial preparation of these dECMs from healthy, young donors for patients who need autologous transplantation. Our study indicated that p38 MAPK inhibitor has a distinctive priming effect on dECM mediated stem cell cartilage regeneration. Combined rejuvenation with sb203580 and dECM expansion can precondition hSDSCs’ resurfacing capacity for osteoarthritic patients with cartilage defects.
机译:自体干细胞是软骨再生的有希望的细胞来源。然而,细胞复制性衰老和关节创伤后炎症为使这种治疗方法取得成果提出了挑战。在这项研究中,我们假设使用p38 MAPK抑制剂(sb203580)进行预处理可在炎性环境中补充脱细胞的细胞外基质(dECM)扩展的人类滑膜衍生干细胞(hSDSC)软骨形成。我们发现,用sb203580进行预处理可大大增强dECM扩展了hSDSC增殖和软骨形成的潜力,而在诱导培养基中补充sb203580则极大地抑制了hSDSC软骨分化,即使对于dECM扩展的细胞也是如此。我们还发现,即使在白介素1(IL-1)诱导的炎症环境中,sb203580预处理也可增强基质扩展的hSDSC软骨形成能力。在异基因dECM上生长的hSDSC中无法检测到HLA-DR表达,表明从健康的年轻供体为需要自体移植的患者商业制备这些dECM的可行性。我们的研究表明,p38 MAPK抑制剂对dECM介导的干细胞软骨再生具有独特的引发作用。结合sb203580的复兴和dECM扩展,可以使hSDSCs具有软骨缺损的骨关节炎患者的换肤能力达到先决条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号